Figure 3From: The safety and immunogenicity of a MF59-adjuvanted H5N1 prepandemic influenza vaccine in healthy adults primed with homologous or heterologous H5N1 vaccines: an observational study Reverse cumulative distribution for hemagglutination inhibition titers against A/Vietnam/1194/2004 three weeks after the second dose. Back to article page